A clinical study of a shingles vaccine in people aged 50 and over (V1)

• Research type

  Research Study

• Full title

  A phase III, randomised, open-label, multicentre clinical trial to assess the safety and immunogenicity of GSK Biologicals’ Herpes Zoster/sub-unit (HZ/su) candidate vaccine when administered subcutaneously as compared to intramuscularly according to a 0,2-month schedule in adults aged 50 years and older

• IRAS ID

  127429

• Contact name

  Nell Wyatt

• Contact email

  n.wyatt@nhs.net

• Sponsor organisation

  GlaxoSmithKline Biologicals

• Eudract number

  2012-005671-14

• ISRCTN Number

  n/a

• REC name

  South Central - Hampshire B Research Ethics Committee

• REC reference

  13/SC/0393

• Date of REC Opinion

  30 Sep 2013

• REC opinion

  Further Information Favourable Opinion